Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade-based Induction and ASCT in Untreated Multiple Myeloma
NCT01215344Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Nov 2010
- Primary completion
- Nov 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Vanderbilt-Ingram Cancer Center. Started Nov 2010; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01215344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01215344.